[ad_1]
In the United States, AstraZeneca may have included outdated product data in its COVID-19 studies, which it developed, reported by US regulators Monday night, following comments from the supervisory board.
1 photoAstraZeneca vaccine. Photo by EPA-Elta
The council “expressed concern that AstraZeneca may have included outdated information from that study, preventing a complete picture of the efficacy data,” the US National Institute of Allergy and Infectious Diseases said in a statement.
“We encourage the company to work with the DSMB (Security and Data Monitoring Board) to review performance data and ensure that the most accurate and up-to-date performance data is released as soon as possible,” the institute said.
AstraZeneca said Monday that phase III vaccine research in the US has shown the company’s vaccine to be 79 percent effective in preventing illness and 100 percent effective in preventing illness and hospitalization.
AstraZeneca has said that it intends to provide the study to the US Food and Drug Administration to allow the vaccine to be used to vaccinate the population.
AstraZeneca is cheaper and easier to store than many other vaccines, but in several countries in Europe and around the world, vaccination with the vaccine was stopped last week due to isolated cases of blood clots after the vaccine.
Last News
I disagree – let’s argue!
Don’t bother with the commenters, but comments with profanity will be automatically removed without apology.
Respublika.lt reserves the right to remove uneducated, profane, unrelated, signed on behalf of another person, breaking the law, advertising spam or inciting crime If you incite violence, racial, national, religious or other hatred, your sparkling words can turn into a one-ton bull when you return; We will provide you with your data upon request of the Lithuanian special services.
[ad_2]
